In early studies, fourth-generation EGFR TKIs—such as EAI045 and JBJ-04-125-02—have been found to be active against C797S-T790M-L858R triple mutant NSCLC when given in association with cetuximab or osimertinib, respectively [15,16]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.